TURNSTONE BIOLOGICS UNVEILS NOVEL VACCINIA ONCOLYTIC VIRAL IMMUNOTHERAPY PLATFORM
January 15, 2025
NEW YORK & OTTAWA, Ontario--(BUSINESS WIRE)--Turnstone Biologics, a clinical-stage immuno-oncology company leading the next generation of oncolytic viral therapies, presented pre-clinical data today supporting the development of a new Vaccinia therapeutic platform at the American Association for Cancer Research Tumor Immunology and Immunotherapy Meeting in Miami. This platform was developed by Dr. John Bell and his colleagues at The Ottawa Hospital Research Institute and the University of Ottawa, and engineered to be potent, highly selective and immune-stimulatory. Furthermore, the versatility of the platform enables additional therapeutic agents to be encoded in the virus and produced at tumor sites. This single platform virus has the potential to create a portfolio of diverse products. Turnstone has exclusively licensed this technology.